Janus Henderson Group PLC Makes New $957,000 Investment in Bausch + Lomb Co. (NYSE:BLCO)

Janus Henderson Group PLC purchased a new stake in Bausch + Lomb Co. (NYSE:BLCO) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 49,633 shares of the company’s stock, valued at approximately $957,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Blue Trust Inc. raised its holdings in shares of Bausch + Lomb by 14,052.2% during the second quarter. Blue Trust Inc. now owns 3,255 shares of the company’s stock worth $47,000 after acquiring an additional 3,232 shares during the period. Squarepoint Ops LLC bought a new position in Bausch + Lomb during the 2nd quarter worth about $173,000. Verition Fund Management LLC acquired a new stake in shares of Bausch + Lomb in the 3rd quarter valued at about $302,000. HighTower Advisors LLC lifted its holdings in shares of Bausch + Lomb by 14.7% in the third quarter. HighTower Advisors LLC now owns 24,661 shares of the company’s stock valued at $476,000 after purchasing an additional 3,164 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Bausch + Lomb by 80.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 29,755 shares of the company’s stock worth $576,000 after buying an additional 13,302 shares during the period. Institutional investors and hedge funds own 11.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Bausch + Lomb in a research note on Thursday. Bank of America reissued an “underperform” rating and issued a $18.00 price objective on shares of Bausch + Lomb in a research report on Thursday. Morgan Stanley lowered shares of Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price target on the stock. in a research note on Monday, December 2nd. Royal Bank of Canada boosted their price target on shares of Bausch + Lomb from $20.00 to $23.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 22nd. Finally, Wells Fargo & Company raised their price objective on Bausch + Lomb from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.58.

Bausch + Lomb Price Performance

Shares of NYSE BLCO opened at $18.60 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.57 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average price is $19.87 and its two-hundred day moving average price is $17.50. The company has a market cap of $6.55 billion, a PE ratio of -17.71, a price-to-earnings-growth ratio of 1.74 and a beta of 0.43. Bausch + Lomb Co. has a twelve month low of $13.16 and a twelve month high of $21.69.

Bausch + Lomb (NYSE:BLCO) last posted its earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.01. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the firm earned $0.22 EPS. The firm’s revenue was up 18.8% compared to the same quarter last year. On average, analysts predict that Bausch + Lomb Co. will post 0.6 EPS for the current year.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.